369
0 Kommentare
Adagene to Present at Investor Conferences in June
SAN DIEGO and SUZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based
therapies, today announced its participation in multiple investor conferences in June 2024.
Adagene’s Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will provide a company update, including progress on the masked, anti-CTLA-4 SAFEbody ADG126. Company management will also host investor meetings.
Jefferies Global Healthcare Conference 2024
- Date: Wednesday, June 5
- Time: 4:30-4:55 PM (Eastern Time)
-
Location: New York City
Goldman Sachs 45th Annual Global Healthcare Conference
- Date: Thursday, June 13
- Time: 10:00-10:35 AM (Eastern Time)
-
Location: Miami
HC Wainwright 2nd Annual Immune Cell Engager Virtual Conference
- Date: Tuesday, June 25
- Time: TBD for presentation
-
Location: Virtual
A live webcast of the presentations will also be accessible in the Investors section of the company’s website at https://www.adagene.com. A webcast replay will be available for at least 30 days.
About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies.
Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with
reputable global partners that leverage its SAFEbody precision masking technology in multiple approaches at the vanguard of science.
Lesen Sie auch
Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody, SAFEbody, and POWERbody technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. The company’s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies in tumor microenvironment, while minimizing on-target off-tumor toxicity in healthy tissues.